Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID-
19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.
Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
remains active.
Articles
Safety and immunogenicity of SARS-CoV-2 recombinant
protein vaccine formulations in healthy adults: interim
results of a randomised, placebo-controlled, phase 1–2,
dose-ranging study
Paul A Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew G Davis, Brandon J Essink, Ian Frank, Owen Haney, Helene Janosczyk,
Michael C Keefer, Marguerite Koutsoukos, Murray A Kimmel, Roger Masotti, Stephen J Savarino, Lode Schuerman, Howard Schwartz,
Lawrence D Sher, Jon Smith, Fernanda Tavares-Da-Silva, Sanjay Gurunathan, Carlos A DiazGranados, Guy de Bruyn
Summary
Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression Lancet Infect Dis 2021;
system being developed against SARS-CoV-2. We present interim safety and immunogenicity results of the first-in- 21: 1257–70
human study of the CoV2 preS dTM vaccine with two different adjuvant formulations. Published Online
April 19, 2021
https://doi.org/10.1016/
Methods This phase 1–2, randomised, double-blind study is being done in healthy, SARS-CoV-2-seronegative adults
S1473-3099(21)00147-X
in ten clinical research centres in the USA. Participants were stratified by age (18–49 years and ≥50 years) and
See Online/Comment
randomly assigned using an interactive response technology system with block randomisation (blocks of varying https://doi.org/10.1016/
size) to receive one dose (on day 1) or two doses (on days 1 and 22) of placebo or candidate vaccine, containing low- S1473-3099(21)00227-9
dose (effective dose 1·3 µg) or high-dose (2·6 µg) antigen with adjuvant AF03 (Sanofi Pasteur) or AS03 This online publication has
(GlaxoSmithKline) or unadjuvanted high-dose antigen (18–49 years only). Primary endpoints were safety, assessed been corrected. The corrected
version first appeared at
up to day 43, and immunogenicity, measured as SARS-C0V-2 neutralising antibodies (geometric mean titres),
thelancet.com/infection on
assessed on days 1, 22, and 36 serum samples. Safety was assessed according to treatment received in the safety June 10, 2022
analysis set, which included all randomly assigned participants who received at least one dose. Neutralising
Department of Medicine,
antibody titres were assessed in the per-protocol analysis set for immunogenicity, which included participants who University of Alabama at
received at least one dose, met all inclusion and exclusion criteria, had no protocol deviation, had negative results Birmingham, AL, USA
(Prof P A Goepfert MD);
in the neutralisation test at baseline, and had at least one valid post-dose serology sample. This planned interim
Sanofi Pasteur,
analysis reports data up to 43 days after the first vaccination; participants in the trial will be followed
Swiftwater, PA, USA
up for 12 months after the last study injection. This trial is registered with ClinicalTrials.gov, NCT04537208, and is (B Fu PhD, M I Bonaparte PhD,
ongoing. O Haney PharmD,
H Janosczyk MA, R Masotti MS,
S J Savarino MD, J Smith PhD,
Findings Between Sept 3 and Sept 29, 2020, 441 individuals (299 aged 18–49 years and 142 aged ≥50 years) were S Gurunathan MD,
randomly assigned to one of the 11 treatment groups. The interim safety analyses included 439 (>99%) of 441 randomly C A DiazGranados MD,
assigned participants (299 aged 18–49 years and 140 aged ≥50 years). Neutralising antibody titres were analysed in G de Bruyn MD); Sanofi
Pasteur, Lyon, France
326 (74%) of 441 participants (235 [79%] of 299 aged 18–49 years and 91 [64%] of 142 aged ≥50 years). There were no
(A-L Chabanon PhD); Rochester
vaccine-related unsolicited immediate adverse events, serious adverse events, medically attended adverse events Clinical Research, Rochester,
classified as severe, or adverse events of special interest. Among all study participants, solicited local and NY, USA (M G Davis MD);
systemic reactions of any grade after two vaccine doses were reported in 81% (95% CI 61–93; 21 of 26) of participants Meridian Clinical Research,
Omaha, NE, USA
in the low-dose plus AF03 group, 93% (84–97; 74 of 80) in the low-dose plus AS03 group, 89% (70–98; 23 of 26) in the
(B J Essink MD); Division of
high-dose plus AF03 group, 95% (88–99; 81 of 85) in the high-dose plus AS03 group, 29% (10–56; five of 17) in the Infectious Diseases, Perelman
unadjuvanted high-dose group, and 21% (8–40; six of 29) in the placebo group. A single vaccine dose did not generate School of Medicine, University
neutralising antibody titres above placebo levels in any group at days 22 or 36. Among participants aged 18–49 years, of Pennsylvania, Philadelphia,
PA, USA (Prof I Frank MD);
neutralising antibody titres after two vaccine doses were 13·1 (95% CI 6·40–26·9) in the low-dose plus AF03 group,
University of Rochester, School
20·5 (13·1–32·1) in the low-dose plus AS03 group, 43·2 (20·6–90·4) in the high-dose plus AF03 group, of Medicine and Dentistry,
75·1 (50·5–112·0) in the high-dose plus AS03 group, 5·00 (not calculated) in the unadjuvanted high-dose group, and Rochester, NY, USA
5·00 (not calculated) in the placebo group. Among participants aged 50 years or older, neutralising antibody titres (Prof M C Keefer MD);
GlaxoSmithKline Vaccines,
after two vaccine doses were 8·62 (1·90–39·0) in the low-dose plus AF03 group, 12·9 (7·09–23·4) in the low-dose
Wavre, Belgium
plus AS03 group, 12·3 (4·35–35·0) in the high-dose plus AF03 group, 52·3 (25·3–108·0) in the high-dose plus AS03 (M Koutsoukos PhD,
group, and 5·00 (not calculated) in the placebo group. L Schuerman MD,
F Tavares-Da-Silva MD); Optimal
Research, Melbourne, FL, USA
Interpretation The lower than expected immune responses, especially in the older age groups, and the high
(M A Kimmel DO); Research
reactogenicity after dose two were probably due to higher than anticipated host-cell protein content and lower than Centers of America, Hollywood,
planned antigen doses in the formulations tested, which was discovered during characterisation studies on the final FL, USA (H Schwartz MD);
bulk drug substance. Further development of the AS03-adjuvanted candidate vaccine will focus on identifying the Peninsula Research Associates,
Rolling Hills Estates, CA, USA
optimal antigen formulation and dose.
(L D Sher MD)
www.thelancet.com/infection Vol 21 September 2021 1257
Articles
Correspondence to: Funding Sanofi Pasteur and Biomedical Advanced Research and Development Authority.
Dr Guy de Bruyn, Sanofi Pasteur,
Swiftwater, PA 18370, USA Copyright © 2021 Elsevier Ltd. All rights reserved.
guy.debruyn@sanofi.com
Introduction and two inactivated vaccines, CoronaVac (Sinovac
COVID-19, caused by SARS-CoV-2, emerged in Biotech) and BBIBP-CorV (Sinopharm).
December, 2019, in Wuhan, China, and a global The SARS-CoV-2 spike (S) glycoprotein on the virion
pandemic was declared in March, 2020. More than surface mediates host-cell entry, making the S protein a
2·8 million deaths and 128·6 million confirmed key target in vaccine development. The introduction of
cases have been reported worldwide (as of double proline substitutions at the beginning of the central
March 31, 2021).1 helix of the S2 subunit of the closely related MERS-CoV
Vaccination against SARS-CoV-2 will probably provide S protein stabilised the protein in a pre-fusion confor-
the most effective interventional long-term means of mation and allowed induction of potent neutra lising
preventing and controlling SARS-CoV-2 infection, and antibody responses in mice.10 Wrapp and colleagues11
it has become an urgent global priority. Of more than successfully applied this stabilising strategy to the SARS-
60 vaccines in clinical development, several have reached CoV-2 S protein. Sanofi Pasteur has developed a candidate
phase 3 testing,2 with interim efficacy results already SARS-CoV-2 recombinant protein vaccine containing the
available for some of these through peer-reviewed stabilised SARS-CoV-2 pre-fusion S protein (CoV2 preS
publications3–5 or public statements.6–9 At the time of dTM). Another adjuvanted recombinant protein vaccine
writing, a number of vaccines had received authorisation candidate (Novavax) containing the stabilised SARS-CoV-2
for conditional, emergency, or temporary use in countries pre-fusion S protein showed robust immunogenicity and
worldwide, including two mRNA-based vaccines, efficacy results, against COVID-19 mild, moderate, and
BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), severe illness in adults, including older adults (aged
a chimpanzee adenovirus-vectored vaccine, ChAdOx1 65 years or older), with acceptable safety.8,12
nCoV-19 (Oxford-AstraZeneca), a non-replicating viral Although recombinant protein vaccines offer the
vector vaccine, Sputnik V (Gamaleya Research Institute), advantages of fewer potential safety concerns and lower
Research in context
Evidence before this study candidates, the antibody responses were higher than antibody
We searched PubMed from database inception to Feb 10, 2021, concentrations in panels of sera from patients recovering from
with no language restrictions, for studies reporting the safety COVID-19.
and immunogenicity of adjuvanted recombinant protein
Added value of this study
vaccine candidates against SARS-CoV-2 using the search terms
This interim analysis represents the first-in-human evaluation of
“vaccine”, “clinical trial”, “SARS-CoV-2”, “recombinant protein”,
our adjuvanted recombinant protein vaccine against SARS-
and “adjuvant”.
CoV-2, CoV2 preS dTM. In this study, although the vaccine raised
One phase 1–2 human trial was retrieved, reporting the preliminary antibodies capable of neutralising wild-type SARS-CoV-2 strains
safety and immunogenicity of a trimeric recombinant full-length in vitro, it had suboptimal immunogenicity, probably due to
spike antigen delivered with Matrix-M adjuvant. The antigen administration of lower antigen doses than planned due to use
shares design similarities with the antigen evaluated in our study of an externally procured reagent in testing. Cytokine profiling
and was manufactured using the same insect-cell expression using ex-vivo whole blood stimulation showed a more robust
system. The adjuvant in the phase 1–2 human trial was a saponin- induction of T-helper-1 cell cytokines than T-helper-2 cell
containing adjuvant, distinct from the oil-in-water based adjuvants cytokines. Reactogenicity after the second dose was greater than
evaluated in this trial. expected, especially among participants receiving the adjuvanted
Two additional vaccine candidates were known to the authors formulations. This greater than expected reactogenicity was
through joint development activities, both of which have probably due to higher than expected levels of host cell proteins
reported preliminary interim results in preprints that were not in the vaccine due to use of an externally procured reagent in
retrieved through the search. One of the studies tested a testing. No other specific safety concerns were noted.
virus-like particle vaccine manufactured in plants, which was
Implications of all the available evidence
found to induce higher antibody titres and cellular responses
Protein vaccines are widely used for vaccine-preventable
when adjuvanted with AS03 than with a second adjuvant.
diseases and represent a reliable and highly scalable technology,
The second study investigated the safety and immunogenicity
with products that can be distributed at 2–8°C, offering clear
of a range of doses of a recombinant trimeric spike-protein
advantages for global distribution. The present vaccine
antigen vaccine manufactured in a mammalian cell line,
candidate will require optimisation of the vaccine antigen
administered without adjuvant or adjuvanted with AS03 or a
formulation and dose before testing in phase 3 trials.
second adjuvant. For both of these AS03-adjuvanted vaccine
1258 www.thelancet.com/infection Vol 21 September 2021
Articles
production costs than other traditional (eg, attenuated or before or after study vaccines); receipt of immunoglobulins,
inactivated) vaccines, they often require the use of blood, or blood-derived products in the past 3 months; and
an adjuvant to enhance the magnitude, quality, and active or previously documented autoimmune disease
persistence of the immune response.13 The antigen dose- (appendix 1). Participants who received another authorised See Online for appendix 1
sparing qualities of adjuvanted formulations, allowing a COVID-19 vaccine were not withdrawn from the study. No
reduced quantity of vaccine antigen to achieve a robust participant received another COVID-19 vaccine during the
immune response compared with antigen alone, are interim analysis period.
particularly pertinent in a pandemic situation, in which The study was done in compliance with the International
there might be potential constraints on antigen supply. Conference on Harmonisation guidelines for Good
We used two different oil-in-water emulsions as vaccine Clinical Practice and the principles of the Declaration of
adjuvant components for the candidate SARS-CoV-2 Helsinki. The protocol and amendments were approved
recombinant protein vaccine, CoV2 preS dTM: the AF03 by applicable Independent Ethics Committees and
adjuvant (Sanofi Pasteur, Marcy l’Etoile, France)14 and Institutional Review Boards and the regulatory agency
the AS03 Adjuvant System (GlaxoSmithKline, Wavre, as per local regulations. Written informed consent was
Belgium).15 obtained from the participants before any study
This interim analysis evaluated the safety and procedures were done.
immunogenicity, including binding and neutralising
antibody responses and cell-mediated immunity, of Randomisation and masking
CoV2 preS dTM, with the goal of informing selection of Participants were stratified by age (18–49 years and
an adjuvant formulation, antigen dose, and immunisation ≥50 years) and randomly assigned to one of 11 different
schedule to proceed to further clinical development. treatment groups to receive one of five candidate vaccine
formulations or placebo, as a single-dose or two-dose
Methods schedule. The candidate vaccine formulations were low-
Study design and participants dose antigen with AF03 or AS03 adjuvant, high-dose
This is an ongoing phase 1–2, randomised, modified antigen with AF03 or AS03 adjuvant, or unadjuvanted
double-blind (unmasked vaccine preparer or adminis- high-dose antigen (appendix 2 p 3). No participant aged See Online for appendix 2
trator, thus person has no role in evaluating the participant 50 years or older was allocated to the unadjuvanted high-
for safety outcomes; masked participant; and masked dose antigen group as older adults are less likely than
outcome assesor), first-in-human, parallel group, placebo- younger adults to respond without the presence of an
controlled, dose-ranging study, with a sentinel safety adjuvant and to minimise the theoretical risk of vaccine-
cohort and early safety data review. The study is ongoing enhanced disease. More participants in the two-dose
across ten clinical research centres in the USA, with a cohort were allocated to receive AS03-adjuvanted
planned duration of approximately 12 months after the formulations than AF03-adjuvanted formulations due to
last study injection. Here, we present interim safety and the substantial clinical and post-marketing experience,
immunogenicity data up to 43 days after first vaccination readiness for large-scale supply, and the extensive and
with the stabilised pre-fusion S protein vaccine, CoV2 multinational regulatory experience with AS03. Groups
preS dTM. were randomly assigned using an inter active response
Healthy adults aged 18 years and older were eligible technology system by a contract research organisation,
for inclusion. A lateral flow immunochromatographic (Calyx, Nottingham, UK). Block randomisation was used,
assay (COVID-19 IgG/IgM Rapid Test Cassette; Healgen with blocks of varying sizes.
Scientific, Houston, TX, USA) was used to identify those Initially, 30 participants aged 18–49 years were enrolled
with recent or previous SARS-CoV-2 infection; the test into a safety sentinel cohort and received a single dose of
was done at each clinical site by trained personnel, the intervention to which they were randomly assigned. A
according to the manufacturer’s instructions. Individuals review of the safety data up to 9 days after the first dose,
testing negative for SARS-CoV-2 antibodies were included unmasked to treatment group, was done by the
in the study. Exclusion criteria included chronic illness or Sanofi Pasteur internal safety committee. Only upon
medical conditions considered to potentially increase the demonstration of acceptable safety were the remaining
risk for severe COVID-19 illness; women who were participants enrolled.
pregnant or lactating; women of childbearing potential Only the study site staff who prepared and administered
who were not using an effective method of contraception the vaccine knew which vaccine was administered, and
or abstinence from at least 4 weeks before the first they were not involved in assessment of study data.
vaccination until at least 12 weeks after the last vaccination;
participation, or planned participation, in another clinical Procedures
trial during the study period; receipt or planned receipt of The preS dTM was produced from a Sanofi Pasteur
any vaccine in the 30 days before the first, or up to 30 days proprietary cell-culture technology based on the insect-
after the last, study vaccination (except for influenza cell baculovirus expression vector system (appendix 2
vaccination, which could be received at least 2 weeks p 5). Purity was determined by sodium dodecyl sulphate
www.thelancet.com/infection Vol 21 September 2021 1259
Articles
polyAcrylamide gel electrophoresis and scanning in which the reference standard was human serum with
densitometry, as described in the appendix 2 (p 5). The known concentration of anti-S protein IgG antibodies;
target quantities of the SARS-CoV-2 preS-antigen per quantitative results were reported in EU/mL.
vaccine dose were 5 µg for the low-dose formulation and A participant subset was randomly selected from
15 µg for the high-dose formulation. However, during the two-dose cohort for evaluation of cell-mediated
characterisation studies (appendix 2 p 5) on the final bulk immunity using an interactive response technology
drug substance, a key polyclonal antibody reagent used system. Immune responses mediated by T-helper-1
to detect the SARS-CoV-2 preS protein was found to also (Th1) and T-helper-2 (Th2) cells were measured from
recognise glycosylated host-cell proteins. As a result, the blood samples obtained on days 1, 22, and 36, after ex-
purity and host-cell protein levels reported for the vivo stimulation, using the TruCulture system (Myriad
phase 1–2 clinical trial materials were inaccurate, and Biosciences, Austin, TX, USA). Blood samples (1 mL)
the concentration of SARS-CoV-2 preS protein in the were drawn directly into the TruCulture tubes,
formulated vaccine product was substantially lower containing 2 mL of buffered media without stimulation
(approximately four to six times) than planned. Upon (negative control), SARS-CoV-2 S protein for specific
recalculation, the effective dose levels administered in a stimulation (S 2P-GCN4, GeneArt), or staphylococcal
0·5 mL vaccine dose in this study were 1·3 µg (low dose) enterotoxin B plus anti-cluster of differentiation 28 for
and 2·6 µg (high dose) of functional SARS-CoV-2 unspecific stimulation (positive control; appendix 2
preS protein. The underdosing of the vaccine formulation p 6). Validated cytokine profiling panels were used to
was discovered after the study was fully enrolled and all evaluate concentrations of interferon-g (IFNg), tumour
participants had received at least one dose of their necrosis factor-α (TNF-α), interleukin (IL)-2, IL-4, IL-5,
assigned product. The differences between the targeted and IL-13 (appendix 2 pp 6–7). When the initial
and the effective dose levels correspond to an excess in regulatory guidances were made public, an emphasis
host-cell protein content in the clinical materials was placed on the need to characterize polarization of
(recalculated host-cell protein content was 3·7 µg in the T-helper responses as Th1 or Th2 predominant. This
low dose formulation and 12·4 µg high dose formulation). was viewed as a safety concern. In this spirit, we have
The AF03 (Sanofi Pasteur)14 and AS03 (GlaxoSmithKline)15 considered the ratio of cytokines as the most efficient
adjuvants are oil-in-water emulsions, described in detail way to summarise these data and address this concern.
in the appendix 2 (p 5).
Vaccine formulations were supplied in two separate Outcomes
vials, one vial containing antigen suspension and another The primary objective was to describe the safety profile of
containing the adjuvant emulsion or phosphate-buffered the candidate vaccine formulations up to 12 months
saline (PBS) diluent. These were mixed before injection after the last dose in all participants. Safety endpoints
to give a final dose volume for injection of 0·5 mL, included immediate unsolicited systemic adverse events
containing 0·25 mL antigen and 0·25 mL adjuvant (occurring within 30 min after each dose); solicited
emulsion or PBS diluent. Placebo recipients received injection-site reactions (pain, erythema, and swelling)
0·5 mL 150 mM NaCl. Vaccine formulations and placebo and solicited systemic reactions (fever, headache, malaise,
were prepared by qualified and trained study personnel and myalgia) up to 7 days after each dose; clinical safety
and administered into the deltoid region of the upper laboratory measures 8 days after the last dose (on day 9
arm by intramuscular injection on day 1 and day 22 for the single-dose cohort and day 30 for the two-dose
(for the two-dose groups only; appendix 2 p 2). cohort); unsolicited adverse events up to 21 days after
Laboratory assessments included serum biochemistry each dose; and medically attended adverse events, serious
tests, haematology (complete blood count with adverse events, and adverse events of special interest,
differential and platelets), and urine analyses. Adverse documented throughout the study. Adverse events of
events were assessed for intensity (grade 1 to grade 3) special interest included anaphylactic reactions and
and their relationship to the study intervention by the potential immune-mediated diseases. Potential immune-
investigator at each site. mediated diseases are a subset of adverse events that
SARS-CoV-2 neutralising antibodies were measured in include autoimmune diseases and other inflammatory or
serum samples with a microneutralisation assay at Sanofi neurological disorders of interest that might have an
Pasteur Global Clinical Immunology Swiftwater, PA, autoimmune aetiology.17 In this interim analysis, we
USA, using the SARS-CoV-2 USA-WA1/2020 strain (BEI describe primary safety endpoints up to day 43.
Resources; catalog number NR-52281). The reduction in The primary immunogenicity objective was to describe
SARS-CoV-2 infectivity, compared with that in the control the neutralising capacity of vaccine-induced antibodies
wells, indicated the presence of neutralising antibodies at days 2, 22, and 36 for each study group. Secondary
in the serum sample. The 50% neutralisation titre objectives for immunogenicity included descriptions
was recorded16 (appendix 2 p 6). Binding antibody of the neutralising antibody profile at days 181 and
concentrations were measured using indirect ELISA 366 (single-dose cohort) or days 202 and 387 (two-dose
done at Nexelis, Laval, Quebec, Canada (appendix 2 p 6), cohort) and the binding antibody profile on days 1, 22,
1260 www.thelancet.com/infection Vol 21 September 2021
Articles
Low-dose plus Low-dose plus High-dose plus High-dose plus Placebo group
AF03 group AS03 group AF03 group AS03 group (n=34)
(n=34) (n=34) (n=34) (n=34)
Aged 18–49 years
Sex
Female 14/24 (58%) 9/24 (38%) 13/24 (54%) 14/24 (58%) 12/24 (50%)
Male 10/24 (42%) 15/24 (62%) 11/24 (46%) 10/24 (42%) 12/24 (50%)
Age, years 36·0 (10·0) 35·4 (8·66) 32·0 (9·69) 29·7 (8·88) 31·1 (8·45)
Race or ethnicity
White 20/24 (83%) 21/24 (88%) 22/24 (92%) 16/24 (67%) 20/24 (83%)
Asian 1/24 (4%) 2/24 (8%) 1/24 (4%) 4/24 (17%) 1/24 (4%)
American Indian or Alaska Native 0 0 0 1/24 (4%) 1/24 (4%)
Black or African American 1/24 (4%) 0 0 1/24 (4%) 0
Multiple 0/24 1/24 (4%) 1/24 (4%) 0 1/24 (4%)
Not reported or unknown 2/24 (8%) 0/24 0/24 2/24 (8%) 1/24 (4%)
Hispanic or Latino 6/24 (25%) 2/24 (8%)* 3/24 (13%) 3/24 (13%) 7/24 (29%)
Aged 50 years or older
Sex
Female 8/10 (80%) 6/10 (60%) 4/10 (40%) 7/10 (70%) 6/10 (60%)
Male 2/10 (20%) 4/10 (40%) 6/10 (60%) 3/10 (30%) 4/10 (40%)
Age, years 59·3 (7·07) 57·3 (5·70) 58·5 (9·29) 61·3 (10·1) 60·1 (7·74)
Race or ethnicity
White 9/10 (90%) 7/10 (70%) 8/10 (80%) 9/10 (90%) 10/10 (100%)
Asian 1/10 (10%) 1/10 (10%) 0 1/10 (10%) 0
Black or African American 0 1/10 (10%) 0 0 0
American Indian or Alaska Native 0 0 0 0 0
Native Hawaiian or Other Pacific Islander 0 1/10 (10%) 0 0 0
Multiple 0 0 1/10 (10%) 0 0
Not reported or unknown 0 0 1/10 (10%) 0 0
Data are n/N (%) or mean (SD). *Hispanic or Latino ethnicity was not reported for one participant in the high-dose plus AF03 group, in the 18–49 years stratum.
Table 1: Participant demographic characteristics (full analysis set) per treatment group for participants in the one-dose cohort
36, 181, and 366 (single-dose cohort) or days 1, 22, 36, Statistical analysis
202, and 387 (two-dose cohort) for each study group. In All analyses were descriptive; there was no hypothesis
this interim analysis, we describe cell-mediated testing. No sample size calculations were done. Approxi-
immuno genicity endpoints up to day 36 (exploratory mately 440 participants were planned to be enrolled into
endpoint). this study (appendix 2 p 3), with 300 participants aged
In an exploratory analysis, neutralising antibody titres 18–49 years (20 participants in each group, except
were measured in a panel of human convalescent serum AS03-adjuvanted groups in the two-dose cohort, with
samples (Sanguine Biobank, iSpecimen, and PPD). 60 participants in each group) and 140 participants aged
Convalescent samples were obtained from 93 donors 50 years or older (ten participants in each group, except
between days 17 and 47 after PCR-positive diagnosis of in AS03-adjuvanted groups in the two-dose cohort, with
COVID-19. Donors had recovered (with clinical severity 30 participants in each group).
ranging from mild to severe) and were asymptomatic at Participant demographic characteristics were described
the time of sample collection. table 1 and table 2 for the full analysis set, which include
Other study objectives include efficacy endpoints, all randomly assigned participants who received at least
specifically the occurrence of virologically confirmed one dose; participants were analysed according to the
COVID-19-like illness and serologically confirmed treatment group to which they were randomly assigned.
SARS-CoV-2 infection, and the association between Safety objectives were assessed in the safety analysis set,
antibody responses to SARS-CoV-2 recombinant protein which included all participants who received at least one
and the risk of virologically confirmed COVID-19-like dose; participants were analysed according to the study
illness or serologically confirmed SARS-CoV-2 infection treatment received. The per-protocol analysis set was
(full list of study objective in appendix 1). These defined as the subset of participants who received at least
prespecified efficacy endpoints will be assessed as part one dose, met all inclusion and exclusion criteria, had
of the ongoing study and reported separately. no protocol deviation, and had negative results in the
www.thelancet.com/infection Vol 21 September 2021 1261
Articles
Low-dose plus Low-dose plus High-dose plus High-dose plus High-dose plus Placebo group
AF03 group AS03 group AF03 group AS03 group unadjuvanted (n=29)
(n=28) (n=82) (n=27) (n=85) group (n=18)
Aged 18–49 years
Sex ·· ·· ·· ·· ·· ··
Female 9/18 (50%) 25/54 (46%) 11/17 (65%) 23/54 (43%) 10/18 (56%) 8/18 (44%)
Male 9/18 (50%) 29/54 (54%) 6/17 (35%) 31/54 (57%) 8/18 (44%) 10/18 (56%)
Age, years 35·3 (8·67) 33·7 (8·99) 32·5 (9·12) 34·9 (8·77) 34·8 (10·2) 32·0 (8·41)
Race or ethnicity ·· ·· ·· ·· ·· ··
White 15/18 (83%) 46/54 (85%) 16/17 (94%) 48/54 (89%) 16/18 (89%) 16/18 (89%)
Asian 2/18 (11%) 4/54 (7%) 0/17 4/54 (7%) 1/18 (6%) 1/18 (6%)
Black or African American 1/18 (6%) 4/54 (7%) 1/17 (6%) 2/54 (4%) 1/18 (6%) 1/18 (6%)
American Indian or Alaska Native 0 0 0 0 0 0
Hispanic or Latino 4/18 (22%) 9/54 (17%) 2/17 (12%) 6/54 (11%) 3/18 (17%) 3/18 (17%)
Aged 50 years or older
Sex ·· ·· ·· ·· ·· ··
Female 5/10 (50%) 11/28 (39%) 7/10 (70%) 21/31 (68%) NA 6/11 (55%)
Male 5/10 (50%) 17/28 (61%) 3/10 (30%) 10/31 (32%) NA 5/11 (45%)
Age, years 58·8 (7·69) 59·8 (6·53) 58·7 (7·92) 61·7 (7·86) NA 61·5 (4·41)
Race or ethnicity ·· ·· ·· ·· ·· ··
White 9/10 (90%) 24/28 (86%) 9/10 (90%) 30/31 (97%) NA 10/11 (91%)
Asian 1/10 (10%) 3/28 (11%) 0 0 NA 0
Black or African American 0 0 0 1/31 (3%) NA 1/11 (9%)
American Indian or Alaska Native 0 1/28 (4%) 0 0 NA 0
Multiple 0 0 1/10 (10%) 0 NA 0
Hispanic or Latino 0 2/28 (7%) 1/10 (10%) 3/31 (10%) NA 0
Data are n/N (%) or mean (SD). NA=not applicable.
Table 2: Participant demographic characteristics (full analysis set) per treatment group for participants in the two-dose cohort
ELISA or neutralisation test at baseline. Neutralising Binding antibody profiles were described based on
and binding antibody profiles were assessed in the per- S-specific antibody geometric mean concentrations
protocol analysis set for immunogenicity, which included measured at days 22 and 36. Antibody concentrations
participants who had at least one valid post-dose serology less than the LLOQ were converted to half the LLOQ
sample within the predefined time window (appendix 1). (appendix pp 6–7).
Cell-mediated immunity analyses were done in a subset 95% CIs for GMTs, geometric mean concentrations,
of participants in the per-protocol analysis set who and GMT ratios were calculated using normal
provided at least one cell-mediated immunity sample approximation of log -transformed titres. 95% CIs for
10
within the predefined time window as per previous proportions were calculated using the Clopper-Pearson
response. Immunogenicity analyses were done according method.18 The differences in seroconversion rates
to the treatment group to which a participant was between groups were computed along with the two-sided
randomly assigned. 95% CIs using the Wilson-Score method without
Neutralising antibody profiles were described based on continuity correction.18
geometric mean titres (GMTs) and 95% CIs. Fold rises in To characterise Th cell polarisation, the pre-vaccination
serum antibody neutralisation titres after vaccination (day 1) to post-vaccination (days 22 or 36) fold cytokine
relative to day 1 were calculated, whereby pre-vaccination rises were computed by treatment group, and ratios of fold
titres below the lower limit of quantification (LLOQ) rises for cytokine pairs (IFNγ and IL-4, IL-5, or IL-13; IL-2
were converted to half the LLOQ. We calculated the and IL-4, IL-5, or IL-13; and TNFα and IL-4, IL-5, or IL-13)
percentage of participants with a four-fold rise in were computed (appendix pp 6–7). Statistical analyses
serum neutralisation titres relative to day 1 at days 22 were done using SAS (version 9.4). This study is ongoing
and 36 (before and after dose). We also calculated the and is registered with ClinicalTrials.gov, NCT04537208.
proportion of participants with seroconversion, which
was defined as detectable neutralisation titres at days 22 Role of the funding source
and 36 in participants with baseline values below the Sanofi Pasteur was involved in the study design, data
LLOQ. collection, data analysis, data interpretation, writing of
1262 www.thelancet.com/infection Vol 21 September 2021
Articles
A
179 participants aged 18–49 years enrolled and randomly assigned
18 assigned to low-dose 54 assigned to low-dose 17 assigned to high-dose 54 assigned to high-dose 18 assigned to high-dose, 18 assigned to placebo
plus AF03 group plus AS03 group plus AF03 group plus AS03 group unadjuvanted group group
18 given first dose on day 1 54 given first dose on day 1 17 given first dose on day 1 54 given first dose on day 1 18 given first dose on day 1 18 given first dose on day 1
1 lost to follow-up
18 in study on day 22 54 in study on day 22 17 in study on day 22 54 in study on day 22 17 in study on day 22 18 in study on day 22
(16 given second dose) (52 given second dose) (17 given second dose) (54 given second dose) (17 given second dose) (18 given second dose)
1 protocol deviation 1 withdrew consent
17 completed the interim 53 completed the interim 17 completed the interim 54 completed the interim 17 completed the interim 18 completed the interim
period period period period period period
B
92 participants aged ≥50 years enrolled and randomly assigned
10 assigned to low-dose plus AF03 30 assigned to low-dose plus AS03 10 assigned to high-dose plus 31 assigned to high-dose plus 11 assigned to high-dose,
group group AF03 group AS03 group unadjuvanted group
2 protocol deviations*
10 given first dose on day 1 28 given first dose on day 1 10 given first dose on day 1 31 given first dose on day 1 11 given first dose on day 1
10 in study on day 22 (10 given 28 in study on day 22 (28 given 10 in study on day 22 (9 given 31 in study on day 22 (31 given 11 in study on day 22 (11 given
second dose) second dose) second dose) second dose) second dose)
10 completed the interim period 28 completed the interim period 10 completed the interim period 31 completed the interim period 11 completed the interim period
Figure 1: Participant flow through the study for those randomised to receive two vaccine doses in the 18–49 years (A) and ≥50 years (B) age strata
*Two participants who were found not to meet all inclusion criteria after randomisation were withdrawn from the study before receiving the first dose.
the report, and the decision to submit the paper for aged ≥50 years; appendix pp 8–9). During randomisation,
publication. the specification of the maximum number of participants
allocated to the single-dose cohort in the younger age
Results stratum did not account for the allocation to the sentinel
Between Sept 3 and Sept 29, 2020, 441 participants were safety cohort. Therefore, among participants in the
randomly assigned (299 aged 18–49 years and 142 aged younger age stratum, more were allocated to the single-
≥50 years). Two participants aged 50 years or older dose cohort and fewer to the two-dose cohort than
from the low-dose plus AS03 group (two-dose planned. The male to female participant ratio was
cohort) did not meet eligibility criteria. Therefore, balanced overall, and across most treatment groups. Most
439 participants received at least one dose and were enrolled participants were White (table 1, table 2).
included in the full analysis set: 269 in the two-dose cohort The reactogenicity profiles (solicited injection-site
(179 participants aged 18–49 years and 90 participants and systemic events) were similar across the adjuvanted
aged ≥50 years; figure 1) and 170 in the single-dose cohort groups in the single-dose cohort (appendix pp 12–13,
(120 participants aged 18–49 years and 50 participants 16–17). Among the adjuvanted vaccine groups in the
www.thelancet.com/infection Vol 21 September 2021 1263
Articles
50
0
two-dose cohort, solicited injection-site reactions (pain, participants who received the low-dose formulation than
erythema, and swelling) during the first 7 days after in participants who received the high-dose formulation
vaccination, including grade 3 reactions, occurred more (two-dose cohort; figure 2; appendix pp 10–12). No grade 3
frequently after the second dose than after the first dose solicited injection-site reactions were observed after the
(figure 2; appendix pp 10–12). Most injection-site reactions first dose in any treatm ent group, and none were observed
occurred on day 0 (pain) or days 1 and 2 (erythema and in the unadjuvanted high-dose or placebo groups after
swelling; appendix pp 14–15). The unadjuvanted high- one or two doses. After the second dose, the highest
dose formulation had a low frequency of injection-site frequency of grade 3 injection-site reactions was seen in
reactions, similar to the placebo group (appendix the high-dose plus AS03 group; the most frequent grade 3
pp 10–12). Overall, pain was the most frequently reported injection-site reaction was erythema (observed in 20 [24%]
injection-site reaction: after dose two, 19 (73%) of of 85 participants in the high-dose plus AS03 group) and
26 participants in the low-dose plus AF03 group, 70 (89%) then swelling (11 [13%] of 85 participants in the high-dose
of 79 in the low-dose plus AS03 group, 19 (73%) of 26 in plus AS03 group). No grade 3 injection-site reactions
the high-dose plus AF03 group, and 78 (92%) of 85 in the were considered serious, and all resolved within a median
high-dose plus AS03 group reported injection-site pain. duration of 2 days.
Solicited injection-site reactions were generally less Among the adjuvanted vaccine groups in the two-dose
frequent and less severe in participants aged 50 years or cohort, solicited systemic reactions (fever, headache,
older than in participants aged 18–49 years across malaise, and myalgia) during the first 7 days after
adjuvanted groups, in partici pants who received the vaccination, including grade 3 reactions, were reported
AF03-adjuvanted formulations than in participants who more frequently after the second dose than after the first
received the AS03-adjuvanted formulations, and in dose in both age strata (figure 3; appendix pp 10–12).
1264 www.thelancet.com/infection Vol 21 September 2021
)%(
stnapicitraP
A After dose one B After dose two
100
Low
do Ls oe
wp l du os
Hs
ieA gF p hl 0 u d3 s
o s
HA
ie
S g0 p hl 3 u ds osA
e
F 0 pl3 us AS Hi03 gh Ld oo ws e dPl
o
La
s
oc
e
e wp b l do u os
Hs
ieA gF p hl 0 u d3 s
o s
HA
ie
S g0 p hl 3 u ds osA
e
F 0 pl3 us AS Hi03 gh Ld oos
w
e P dl oa Lsc oee wb p lo du os
Hs
ieA gF p hl 0 u d3 s
o s
HA
ie
S g0 p hl 3 u ds osA
e
F 0 pl3 us AS Hi03 gh dose Placebo
Low
do Ls oe
wp l du os
Hs
ieA gF p hl 0 u d3 s
o s
HA
ie
S g0 p hl 3 u ds osA
e
F 0 pl3 us AS Hi03 gh Ld oo ws e dPl
o
La
s
oc
e
e wp b l do u os
Hs
ieA gF p hl 0 u d3 s
o s
HA
ie
S gp0 hl 3 u ds osA
e
F 0 pl3 us AS Hi03 gh Ld oos
w
e P dl oa Lsc oee wb p lo du os
Hs
ieA gF p hl 0 u d3 s
o s
HA
ie
S g0 p hl 3 u ds osA
e
F 0 pl3 us AS Hi03 gh dose Placebo
50
0
Low
dose
L
opl wu s
d
oA sF
He
i0 p g3 l hu s
d
oA sS
e
H
0 ip3 gl hu s
d
oA sF
e
0 p3 lus AS L0 o3 wP l da oc se
e
Lb oo pl wu s
d
oA sF
He
i
0 gp3 l
h
us
d
oA sF
He
i
0 gp3 l
h
us
d
oA sS
e
0 p3 lus AS L03
o
wP l dac ose
e
Lb oo pl wu s
d
oA sF
He
i0 p g3 l hu s
d
oA sS
He
i
0 gp3 l
h
u ds oA sF
e
0 p3 lus AS03 Placebo
)%(
stnapicitraP
Grade 1
Grade 2
Grade 3
Pain Erythema Swelling Pain Erythema Swelling
C D
100
Low
dose
L
opl wu s
d
oA sF
He
i0 p g3 l hu s
d
oA sS
e
H
0 ip3 gl hu s
d
oA sF
e
0 p3 lus AS L0 o3 wP l da oc se
e
Lb oo pl wu s
d
oA sF
He
i0 p g3 l hu s
d
oA sS
e
H
0 ip3 gl hu s
d
oA sF
e
0 p3 lus AS L03
o
wP l dac ose
e
Lb oo pl wu s
d
oA sF
He
i0 p g3 l hu s
d
oA sS
e
H
0 ip3 gl hu s
d
oA sF
e
0 p3 lus AS03 Placebo
Pain Erythema Swelling Pain Erythema Swelling
Figure 2: Frequency of solicited injection-site reactions after the first or second dose in participants from the two-dose cohort
Articles
50
0
Systemic reactions occurred most frequently on day 2 high-dose plus AS03 group. Grade 3 systemic reactions
after the second dose (appendix pp 14–15). Systemic also occurred more frequently after the second dose than
reactions were generally less frequent and less severe in after the first dose among the adjuvanted formulations,
participants aged 50 years or older than in those with the highest frequency in the low-dose plus AS03
in the younger age group, and in participants who group (grade 3 headache, malaise, and myalgia occurred
received AF03-adjuvanted formulations than in those in nine [11%] of 80 participants, 13 [17%] of 79 participants,
who received the AS03-adjuvanted formulations. The and 11 [14%] of 80 participants, respectively), high-dose
frequency of solicited systemic reactions among the plus AS03 group (grade 3 headache, malaise, and myalgia
unadjuvanted high-dose vaccine and placebo groups in occurred in six [7%], 14 [17%], and nine [11%] of
the two-dose cohort was low and similar in both groups 85 participants, respectively), and high-dose plus AF03
(figure 3; appendix pp 10–12). Myalgia, malaise, and group (grade 3 headache, malaise, and myalgia occurred
headache were the most commonly reported solicited in one [3%], three [12%], and three [12%] of 26 participants,
systemic reactions after the second dose of adjuvanted respectively; figure 3; appendix pp 11–12). No grade 3
vaccine, with frequencies ranging from 46% (12 of solicited systemic reactions were considered serious, and
26 participants; for myalgia in the low-dose plus AF03 all resolved with a median duration of 2 days.
group) to 76% (65 of 85 participants; for myalgia in the No vaccine-related immediate unsolicited reactions
high-dose plus AS03 group; appendix pp 11–12). Fever were observed in any group (appendix pp 18–20). We
was reported after the second dose in four (15%) of observed an increase in the number of unsolicited
26 participants in the low-dose plus AF03 group, 28 (36%) adverse events after the second dose compared with
of 78 in the low-dose plus AS03 group, five (19%) of 26 in placebo, mainly in the AS03 groups, with a small number
the high-dose plus AF03 group, and 23 (27%) of 84 in the of grade 3 reactions, primarily due to reporting of
www.thelancet.com/infection Vol 21 September 2021 1265
)%(
stnapicitraP
A After dose one, participants aged 18–49 years B After dose two, participants aged 18–49 years
100
Low Ld oos we d
Hp il
o
gsus
he
dA p Hl iF ou
s
g0 s
e
h3 A p dlS ou0 ss3
e
A pF l0 us3 A Hi LS g o0 h3
w
d do LP os l ose a
e w
c e p
d
Hl ib ou go ss
he
A dpF Hl io0 u
s
gs3
e h
A p dlS ou0 ss3
e
A pF l0 us3 A Hi LS g o0 h3
w
d
d
Lo oPs ol se a
e w
c pe
d
Hl ib ou gso s
he
A dpF Hl io0 u
s
gs3
e h
A p dlS ou0 ss3
e
A pF l0 us3 A Hi LS g o0 h3
w
d do LP os l ose a
e w
c e p
d
Hl ib ou go ss
he
A dpF Hl io0 u
s
gs3
e h
A p dlS ou0 ss3
e
A pF l0 us3 A HiS g0 h3 do Ps le acebo
50
0
Low
d Los oe
w
pl du
o
Hs
is e
g
A hpF l0 du3 os sA
e
S p0 l3 us AS Hi0 g3 Lh od wo s dPe l Loa
s
oc
e
we pb l do u
o
Hs
is e
g
A hpF l0 du3 os sA
e
S p0 l3 us AS Hi0 g3 Lh od
w
os dPe
L
ol
s
oa ec we pl db u oo Hs
is e
g
A hpF l0 du3 os sA
e
S p0 l3 us AS Hi0 g3 Lh od wo s dPe l Loa
s
oc
e
we pb l do u
o
Hs
is e
g
A hpF l0 du3 os sA
e
S p0 l3 us AS Hi0 g3 h dos Pe lacebo
)%(
stnapicitraP
Grade 1
Grade 2
Grade 3
Low Ld oos we d
Hp il
o
gsus
he
dA p Hl iF ou
s
g0 s
e
h3 A p dlS ou0 ss3
e
A pF l0 us3 A Hi LS g o0 h3
w
d do LP os l ose a
e w
c e p
d
Hl ib ou go ss
he
A dpF Hl io0 u
s
gs3
e h
A p dlS ou0 ss3
e
A pF l0 us3 A Hi LS g o0 h3
w
d
d
Lo oPs ol se a
e w
c pe
d
Hl ib ou gso s
he
A dpF Hl io0 u
s
gs3
e h
A p dlS ou0 ss3
e
A pF l0 us3 A Hi LS g o0 h3
w
d do LP os l ose a
e w
c e p
d
Hl ib ou go ss
he
A dpF Hl io0 u
s
gs3
e h
A p dlS ou0 ss3
e
A pF l0 us3 A HiS g0 h3 do Ps le acebo
Fever Headache Malaise Myalgia Fever Headache Malaise Myalgia
C After dose one, participants aged 50 years or older D After dose two, participants aged 50 years or older
100
Low
d Los oe
w
pl du
o
Hs
is e
g
A hpF l0 du3 os sA
e
S p0 l3 us AS Hi0 g3 Lh od wo s dPe l Loa
s
oc
e
we pb l do u
o
Hs
is e
g
A hpF l0 du3 os sA
e
S p0 l3 us AS Hi0 g3 Lh od
w
os dPe
L
ol
s
oa ec we pl db u oo Hs
is e
g
A hpF l0 du3 os sA
e
S p0 l3 us AS Hi0 g3 Lh od wo s dPe l Loa
s
oc
e
we pb l do u
o
Hs
is e
g
A hpF l0 du3 os sA
e
S p0 l3 us AS Hi0 g3 h dos Pe lacebo
Fever Headache Malaise Myalgia Fever Headache Malaise Myalgia
Figure 3: Frequency of solicited systemic reactions after the first or second dose in participants from the two-dose cohort
Articles
100 000
10 000
1000
100
10
1
Day 1 Day 22 Day 36
reactogenicity-type (local and systemic) events (appendix group (figure 4A). Among participants aged 50 years
p 18). Three serious adverse events were reported (two in or older, neutral ising antibody titres after two vaccine
the single-dose cohort, one each in the low-dose plus doses were 8·62 (1·90–39·0) in the low-dose plus
AF03 and high-dose plus AF03 groups; and one in the AF03 group, 12·9 (7·09–23·4) in the low-dose
two-dose cohort in the high-dose plus AS03 group). plus AS03 group, 12·3 (4·35–35·0) in the high-dose plus
All three were deemed not related to the vaccine AF03 group, 52·3 (25·3–108·0) in the high-dose plus
by the investigator and the sponsor, and none led to AS03 group, and 5·00 (not calculated) in the placebo
discontinuation from the study. These serious adverse group. The GMT for the pooled convalescent serum panel
events included one transient ischaemic attack in a was 72·4 (95% CI 17·6–297·5; figure 4A). After dose two,
participant with a history of ocular occlusion and GMTs observed with the unadjuvanted high-dose
treatment with antiplatelet drugs, who did not receive formulation did not differ substantially from those in the
a second dose; one hip fracture after the first dose in placebo group. AF03-adjuvanted and AS03-adjuvanted
a participant who remained in the study; and one high-dose formul ations yielded approximately three-fold
participant who developed breast cancer, who had and four-fold higher GMTs, respectively, than did their
symptoms before study vaccination, and did not receive low-dose formulation counterparts: GMTs on day 36 were
a second dose. There were no potential immune- 30·2 (95% CI 16·3–55·9) in the high-dose plus AF03
mediated diseases reported and there were no adverse group and 67·6 (47·9–95·4) in the high-dose plus
events of special interest, serious adverse events, or AS03 group versus 11·7 (6·50–20·9) in the low-dose plus
severe medically attended adverse events considered to AF03 group and 17·2 (12·1–24·5) in the low-dose
be related to study vaccine by the investigator in any plus AS03 group (both age strata combined).
group (up to day 43 of the study). At day 36, the proportion of all participants
A single vaccine dose did not generate neutralising independently from the age group with a four-fold rise in
antibody titres above placebo levels in any group neutralising antibody titres was 29·4% (95% CI
at days 22 or 36 (appendix p 22). Among participants aged 10·3–56·0; 5 of 17) in the low-dose plus AF03 group,
18–49 years, neutralising antibody GMTs after 37% (25–50; 23 of 63) in the low-dose plus AS03 group,
two doses were 13·1 (95% CI 6·40–26·9) in the low-dose 75% (63·0–84·7; 51 of 68) in the high-dose plus AF03
plus AF03 group, 20·5 (13·1–32·1) in the low-dose group, and 67% (43·0–85·0; 14 of 21) in the high-dose
plus AS03 group, 43·2 (20·6–90·4) in the high-dose plus plus AS03 group (appendix p 23). In the post-hoc analysis,
AF03 group, 75·1 (50·5–112·0) in the high-dose plus the proportion of participants with a four-fold rise in
AS03 group, 5·00 (not calculated) in the unadjuvanted neutralising antibody titres was lower in the 50 years or
high-dose group, and 5·00 (not calculated) in the placebo older than in the 18–49 years age groups, particularly
1266 www.thelancet.com/infection Vol 21 September 2021
,noitartnecnoc
naem
cirtemoeG
)IC
%59(
Lm/UE
1000
100
10
1
Convalescent
B serum
Day 1 Day 22 Day 36
Participants aged 18–49 years Participants aged 50 years or older
,sertit
naem
cirtemoeG
)IC
%59(
lid/1
A
Low dose plus
AF03
Low dose plus
AS03
High dose plus
AF03
High dose plus
AS03
Placebo
High dose
Figure 4: Neutralising (A) and binding (B) antibody responses after the first and second doses by age group
Data for the two-dose cohort; per-protocol analysis set for immunogenicity. Neutralising antibody titres are additionally shown for a panel of 93 convalescent serum
samples as indicated in (A).
Articles
for participants aged 60 years or older (range across SARS-CoV-2 candidate vaccines.19–22 In SARS-CoV-2-
vaccine groups for ≥60 years was from 0% [0–98; 0 of one] seronegative participants aged 18–49 years, two doses of
in the low-dose plus AF03 group to 50% [16–84; four of the adjuvanted candidate vaccine formulations were
eight] in the high-dose plus AS03 group; appendix p 23). needed to generate neutralising antibody titres of a similar
Seroconversion for neutralising antibody titres at day 36 magnitude to those measured in patients recovering from
was observed in 47% (95% CI 23–72; eight of 17) of PCR-confirmed infection (convalescent serum titres). The
participants in the low-dose plus AF03 group, 52% (39–65; need for an adjuvant was shown as the unadjuvanted high-
33 of 63) in the low-dose plus AS03 group, 71% (48–89; dose group did not elicit a neutralising antibody response.
15 of 21) in the high-dose plus AF03 group, and Neutralising antibody titres among participants aged
88% (78–95; 60 of 68) in the high-dose plus AS03 group; 50 years or older were lower than those in the younger age
appendix p 23). The proportion with seroconversion was group, showing an age effect with the formulations
lower in participants aged 50 years or older, particularly evaluated. This effect was further evidenced by lower
those aged 60 years or older, than in participants aged proportions of participants aged 50 years or older than
18–49 years (range across vaccine groups for ≥60 years aged 18–49 years with a four-fold rise in neutralising
was from 0% [0–98; 0 of 1] in the low-dose plus AF03 antibody titres and who seroconverted, particularly those
group to 63% [25–92; five of eight] in the high-dose plus aged 60 years and older, a key population at risk of severe
AS03 group; appendix p 23). illness after infection with SARS-CoV-2. The high-dose
Binding antibody responses were noted in the single formulation given with either AS03 or AF03 resulted in
dose cohort, although geometric mean concentrations higher neutralising responses than the corresponding low-
were ten-times lower than the corresponding two-dose dose formulation. The high-dose plus AS03 formulation
group and none of the groups achieved higher than consistently showed more robust neutralising and binding
90% binding antibody seroconversion at D36 whereas antibody responses compared with the other candidate
100% binding antibody seroconversion was achieved vaccine formulations. However, not all participants in the
in all of the two-dose adjuvanted vaccine groups (two dose high-dose plus AS03 group had seroconversion of
groups Figure 4B; single dose groups appendix p 22). neutralising antibodies after the second dose, especially
Some increases in binding antibody geometric mean among older participants (63% [95% CI 24·5–91·5] of
concentrations were measured after the first dose, but those aged ≥60 years).
greater increases were evident after the second dose in Previous human experimental coronavirus infection
both age groups (figure 4B). Responses were higher in the studies identified that the presence of pre-challenge
AS03-adjuvanted groups than in the AF03-adjuvanted neutralising antibodies was predictive of protection from
groups, and higher in the high-dose groups than the low- infection or symptoms after challenge.23,24 A growing
dose groups; a small increase compared with placebo body of evidence from animal models suggests a key role
at day 36 was observed in the unadjuvanted for humoral responses, and specifically neutralising
high-dose group. antibody responses, in protection against SARS-CoV-2.
Cell-mediated immunity was assessed in a subset of A study showed that adoptive transfer of purified IgG
87 participants from the two-dose cohort: 60 participants from convalescent macaques protected naive recipient
aged 18–49 years (18 per group for the AS03-adjuvanted rhesus macaques against SARS-CoV-2 challenge in a
vaccine groups; six per group for all other study groups) dose-dependent manner, with reasonably low neutralising
and 27 participants aged 50 years and older (nine per antibody titres sufficient to protect against SARS-CoV-2 in
group in AS03-adjuvanted groups; three per group in all this model.25 High neutralising antibody titres were able
other study groups). Increases of IFN-γ, IL-2, and TNFα to achieve full protection in macaques, whereas ten-fold
cytokines from pre-vaccination to days 22 and 36 tended lower titres could still attain partial protection. These data
to be more robust than were the increases for IL-4, IL-5, suggest that neutralising antibodies might be sufficient
and IL-13, especially in the AS03-adjuvanted groups, for protection, even in the absence of cellular and innate
suggesting no Th2 cell bias in the cell-mediated immune responses.25 Our findings indicate that, although
responses (appendix p 24). the best performing candidate vaccine formulation
among younger adults was similar in terms of neutralising
Discussion titres to the titres seen in convalescent serum titres, the
In this descriptive, first-in-human study, a recombinant, responses in older participants were notably lower than
pre-fusion stabilised trimeric SARS-CoV-2 S-antigen, convalescent serum titres.
formulated with either AS03 or AF03 oil-in-water-based The poor antibody responses observed in this study
adjuvants, elicited neutralising antibodies with no are most likely due to the use of substantially lower
specific safety concerns that preclude further development. antigen doses than planned. Although other factors, for
Furthermore, a non-Th2 cell biased cytokine response was example poor characterisation of the expressed antigen
generated in AS03-adjuvanted vaccine groups, with IFN-γ or product matrix, or failure during bedside mixing,
production consistent with previous observations using could theoretically lead to poor immune responses to the
the AS03 adjuvant system in influenza, hepatitis B, and candidate vaccine formulations, these are unlikely given
www.thelancet.com/infection Vol 21 September 2021 1267
Articles
the extensive characterisation undertaken in our study. characterisation of S protein and host-cell protein content.
Nevertheless, further development of the manufacturing Although a high host-cell protein content has been
process and assays to support characterisation of antigen administered historically in the context of clinical
content were ongoing in parallel to this first-in-human development of a recombinant influenza vaccine using the
trial. Polyclonal sera used in antigen characterisation same manufacturing platform, no such levels of host-cell
were discovered, after the study had commenced, to also proteins have been previously administered in combination
bind to host-cell proteins, resulting in an overestimation with an adjuvant or in a two-dose injection schedule. In
of the S-antigen content during manufacture and under- future clinical studies with the CoV2 preS dTM vaccine we
estimation of the host-cell protein content. Therefore, therefore plan to use clinical material with host-cell protein
although the observed antibody responses support the content below that of the low-dose group in the present
selection of the AS03 adjuvant for further development, study, with the aim of improving the reactogenicity profile.
they also indicate that further optimisation of the antigen There was no other medically relevant safety observation
formulation or purification process and antigen dosage during the interim study period (up to day 43). Safety
for the selected AS03-adjuvanted candidate vaccine is monitoring continues for up to 12 months after
required. It should be noted that such evolution of administration of the second vaccine dose.
manufacturing and production methods is typical during A previously postulated theoretical safety concern
the development pathway but has been accelerated with SARS-CoV-2 vaccines is the risk of potentiating
necessarily for COVID-19 vaccine development. immunopathology in vaccine recipients upon exposure to
No vaccine-related serious adverse events, adverse wild-type virus. Various hypothetical risk factors have
events of special interest, or severe medically attended been proposed, including the magnitude of the immune
adverse events were reported after either one or two responses, the balance between binding and functional
vaccine doses. There was a higher than anticipated antibodies, the induction of antibodies with functional
number and severity of local and systemic solicited characteristics such as binding to particular Fc receptors,
reactions after the second dose of the adjuvanted vaccine and the nature of the Th2 cell response, with Th2-polarised
formulations, with the highest frequency in the high-dose cellular responses being proposed to contribute to
plus AS03 groups. These reactions were generally less immunopathology.34–37 In this interim analysis, there was
frequent and milder in the older adults than in younger no evidence of vaccine-mediated disease enhancement.
adults. The unadjuvanted high-dose formulation The results from our cell-mediated immunity analysis do
generated similar reactogenicity profiles to placebo. not support a bias towards Th2 polarisation after the first
Overall, these solicited local and systemic reactions were or second dose of the AS03-adjuvanted candidate vaccine
not serious, lasted a median of 2 days, and fully resolved. formulations; rather, we observed a consistent Th1
Although we did not assess a potential association response, as measured through IFNg, combined with
of reactogenicity with the magnitude of the immune low levels of Th2 responses, as measured through IL-4,
response, it is notable that both were greatest in the high- IL-5, and IL-13. Although there is currently no evidence
dose plus AS03 groups of the two-dose cohort. Although of any candidate SARS-CoV-2 vaccine giving rise to the
transient, the reactogenicity profile observed after the phenomenon of vaccine-mediated enhanced disease, the
second dose in the adjuvanted groups showed more observed cell-mediated immunity profile is reassuring.
frequent and more severe reactions than those reported The main limitation of this study is the erroneous
in previous studies of influenza vaccine candidates (two- characterisation of the content of protein and host-cell
dose schedules) containing the same adjuvants26–29 and proteins used in the filled clinical materials administered
the reactogenicity profiles reported for other SARS-CoV-2 in the trial, resulting in a substantially lower concen-
vaccine candidates using AS03-adjuvanted recombinant tration of SARS-CoV-2 S protein in the formulated
S proteins (Medicago [NCT04450004]22 and Clover vaccine product than expected, and a correspondingly
Biopharmaceuticals [NCT04405908]). Notably, high levels higher host-cell protein content. Other limitations
of reactogenicity have been described during the clinical include the necessarily small numbers of participants in
development of other SAR-CoV-2 vaccines, including the this phase 1–2 study, such that rare serious adverse
two recently authorised mRNA vaccines (BioNTech-Pfizer events and adverse events of special interest might
and Moderna),30,31 as well as for the Janssen adenovirus not have been captured. Furthermore, an error in the
vector vaccine,32 the Novavax recombinant CoV2 preS specification of the caps on group sizes during
vaccine (containing Matrix-M1 adjuvant),12 and the randomisation resulted in more participants in the
candidate mRNA-based vaccine CVnCoV (Curevac).33 younger age stratum being allocated to the single-dose
We hypothesised that the high levels and severity of the cohort and fewer participants in the two-dose cohort
reactogenicity observed in our study might be explained by than planned. Further analysis of the cell-mediated
the higher than anticipated content of host-cell protein in immune responses is ongoing; in particular, cellular
the clinical material (estimated at approximately 3·7 μg per profiling will help determine the source of cytokines
vaccine dose in the low-dose groups and 12·4 μg per dose detected during ex-vivo stimulation of whole blood as
in the high-dose groups) resulting from the erroneous described here.
1268 www.thelancet.com/infection Vol 21 September 2021
Articles
The results from the candidate vaccine formulations 9 National Institutes of Health. News Release. Janssen investigational
tested here are informative in terms of the neutralising COVID-19 vaccine: interim analysis of phase 3 clinical data released.
https://www.nih.gov/news-events/news-releases/janssen-
and binding antibody responses generated in healthy investigational-COVID-19-vaccine-interim-analysis-phase-3-clinical-
adults. Further improvement of the preS vaccine antigen data-released (accessed Feb 18, 2021).
formulation is needed to identify the optimal vaccine 10 Pallesen J, Wang N, Corbett KS, et al. Immunogenicity and
structures of a rationally designed prefusion MERS-CoV spike
dose before evaluation in larger-scale phase 3 trials.
antigen. Proc Natl Acad Sci USA 2017; 114: E7348–57.
Contributors 11 Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the
BF, A-LC, MIB, CAD, and GdB contributed to the concept or design of the 2019-nCoV spike in the prefusion conformation. Science 2020;
367: 1260–63.
study; PAG, MGD, BJE, IF, HJ, MCK, MAK, RM, HS, LDS, and JS
contributed to data acquisition. PAG, BF, A-LC, MIB, OH, SJS, LS, FT-D-S, 12 Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2
recombinant spike protein nanoparticle vaccine. N Engl J Med 2020;
MK, SG, CAD, and GDB were involved in the analysis and interpretation of
383: 2320–32.
the data. All authors were involved in drafting or critically revising the
13 Nascimento IP, Leite LCC. Recombinant vaccines and the
manuscript, and all authors approved the final version and are accountable
development of new vaccine strategies. Braz J Med Biol Res 2012;
for the accuracy and integrity of the manuscript. All authors had full access
45: 1102–11.
to all the data in the study and had final responsibility for the decision to
14 Klucker MF, Dalençon F, Probeck P, Haensler J. AF03, an alternative
submit for publication. At least two authors (PAG and GDB) have accessed
squalene emulsion-based vaccine adjuvant prepared by a
and verified the data. phase inversion temperature method. J Pharm Sci 2012;
Declaration of interests 101: 4490–500.
BF, A-LC, MIB, OH, HJ, RM, SJS, JS, SG, CAD, and GdB are Sanofi 15 Garçon N, Vaughn DW, Didierlaurent AM. Development and
Pasteur employees. A-LC, OH, HJ, SJS, SG, CAD, and GdB hold stock. evaluation of AS03, an adjuvant system containing α-tocopherol
MK, LS, and FT-D-S are employed by, and hold restricted shares in, the and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012;
11: 349–66.
GlaxoSmithKline group of companies. IF reports grants from Janssen
and personal fees from Gilead and ViiV Healthcare. All other authors 16 Kalnin KV, Plitnik T, Kishko M, et al. Immunogenicity of novel
mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human
declare no competing interests.
primates. bioRxiv 2020; published online Oct 14.
Data sharing https://doi.org/10.1101/2020.10.14.337535 (preprint).
Qualified researchers can request access to patient-level data and related 17 Tavares Da Silva F, De Keyser F, Lambert PH, Robinson WH,
study documents, including the clinical study report, study protocol with any Westhovens R, Sindic C. Optimal approaches to data collection and
amendments, blank case report form, statistical analysis plan, and dataset analysis of potential immune mediated disorders in clinical trials of
specifications. Patient-level data will be anonymised and study documents new vaccines. Vaccine 2013; 31: 1870–76.
will be redacted to protect the privacy of trial participants. Further details on 18 Newcombe RG. Two-sided confidence intervals for the single
Sanofi’s data sharing criteria, eligible studies, and process for requesting proportion: comparison of seven methods. Stat Med 1998;
17: 857–72.
access can be found at https://www.clinicalstudydatarequest.com.
19 Díez-Domingo J, Baldó JM, Planelles-Catarino MV, et al. Phase II,
Acknowledgments randomized, open, controlled study of AS03-adjuvanted H5N1
The authors thank all participants, investigators, and study site personnel pre-pandemic influenza vaccine in children aged 3 to 9 years:
who took part in this study. The authors acknowledge Juliette Gray of follow-up of safety and immunogenicity persistence at 24 months
inScience Communications, Springer Healthcare, London, UK, for post-vaccination. Influenza Other Respir Viruses 2015; 9: 68–77.
providing editorial assistance with the preparation of this manuscript, 20 Leroux-Roels G, Marchant A, Levy J, et al. Impact of adjuvants on
funded by Sanofi Pasteur. The authors also thank Isabel Grégoire for CD4(+) T cell and B cell responses to a protein antigen vaccine:
providing editorial assistance and manuscript coordination on behalf of results from a phase II, randomized, multicenter trial.
Sanofi Pasteur. Funding was provided by Sanofi Pasteur and the Clin Immunol 2016; 169: 16–27.
US Government through Biomedical Advanced Research and 21 Moris P, van der Most R, Leroux-Roels I, et al. H5N1 influenza
Development Authority under contract HHSO100201600005I. vaccine formulated with AS03 A induces strong cross-reactive and
polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31: 443–54.
References 22 Ward BJ, Gobeil P, Séguin A, et al. Phase 1 trial of a candidate
1 Dong E, Du H, Gardner L. An interactive web-based dashboard to recombinant virus-like particle vaccine for covid-19 disease
track COVID-19 in real time. Lancet Infect Dis 2020; 20: 533–34. produced in plants. medRxiv 2020: published online Nov 6.
2 WHO. Draft landscape of COVID-19 candidate vaccines. https:// https://doi.org/10.1101/2020.11.04.20226282 (preprint).
www.who.int/publications/m/item/draft-landscape-of-covid-19- 23 Callow KA. Effect of specific humoral immunity and some non-
candidate-vaccines (accessed Oct 26, 2020). specific factors on resistance of volunteers to respiratory
3 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the coronavirus infection. J Hyg (Lond) 1985; 95: 173–89.
BNT162b2 mRNA covid-19 vaccine. N Engl J Med 2020; 383: 2603–15. 24 Reed SE. The behaviour of recent isolates of human respiratory
4 Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the coronavirus in vitro and in volunteers: evidence of heterogeneity
ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: among 229E-related strains. J Med Virol 1984; 13: 179–92.
an interim analysis of four randomised controlled trials in Brazil, 25 McMahan K, Yu J, Mercado NB, et al. Correlates of protection
South Africa, and the UK. Lancet 2021; 397: 99–111. against SARS-CoV-2 in rhesus macaques. Nature 2020; 590: 630–34.
5 Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and 26 Cohet C, van der Most R, Bauchau V, et al. Safety of AS03-adjuvanted
efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost influenza vaccines: a review of the evidence. Vaccine 2019; 37: 3006–21.
COVID-19 vaccine: an interim analysis of a randomised controlled
27 Jackson LA, Campbell JD, Frey SE, et al. Effect of varying doses of a
phase 3 trial in Russia. Lancet 2021; 397: 671–81.
monovalent H7N9 influenza vaccine with and without AS03 and
6 US Food and Drug Administration. Vaccines and related biological MF59 adjuvants on immune response: a randomized clinical trial.
products advisory committee meeting December 17, 2020. https:// JAMA 2015; 314: 237–46.
www.fda.gov/media/144434/download (accessed Dec 28, 2020).
28 Levie K, Leroux-Roels I, Hoppenbrouwers K, et al. An adjuvanted,
7 Sinopharm - Beijng Institute of Biological Products. Press release low-dose, pandemic influenza A (H5N1) vaccine candidate is safe,
[Chinese]. http://sinopharm.com/en/s/1395-4173-38862.html immunogenic, and induces cross-reactive immune responses in
(accessed Feb 1, 2021). healthy adults. J Infect Dis 2008; 198: 642–49.
8 Novavax. Novavax COVID-19 vaccine demonstrates 89·3% efficacy 29 Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M. Assessment
in UK phase 3 trial. Press release. Jan 28, 2021. https://ir.novavax. of squalene adjuvanted and non-adjuvanted vaccines against
com/news-releases/news-release-details/novavax-covid-19-vaccine- pandemic H1N1 influenza in children 6 months to 17 years of age.
demonstrates-893-efficacy-uk-phase-3 (accessed Feb 10, 2021). Hum Vaccin Immunother 2012; 8: 1283–92.
www.thelancet.com/infection Vol 21 September 2021 1269
Articles
30 Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine 34 Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified
against SARS-CoV-2—preliminary report. N Engl J Med 2020; vaccinia virus Ankara based recombinant SARS vaccine in ferrets.
383: 1920–31. Vaccine 2005; 23: 2273–79.
31 Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of 35 Lambert P-H, Ambrosino DM, Andersen SR, et al. Consensus
COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; summary report for CEPI/BC March 12–13, 2020 meeting:
586: 589–93. assessment of risk of disease enhancement with COVID-19
32 Sadoff J, Le Gars M, Shukarev G, et al. Safety and immunogenicity vaccines. Vaccine 2020; 38: 4783–91.
of the Ad26.COV2.S COVID-19 vaccine candidate: interim results 36 Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with
1 of a phase 1/2a, double-blind, randomized, placebo-controlled SARS coronavirus vaccines leads to pulmonary immunopathology
trial. medRxiv 2020; published online Sept 25. https://doi. on challenge with the SARS virus. PLoS One 2012; 7: e35421.
org/10.1101/2020.09.23.20199604 (preprint). 37 Yasui F, Kai C, Kitabatake M, et al. Prior immunization with severe
33 Kremsner P, Mann P, Bosch J, et al. Phase 1 assessment of the safety acute respiratory syndrome (SARS)-associated coronavirus
and immunogenicity of an mRNA-lipid nanoparticle vaccine (SARS-CoV) nucleocapsid protein causes severe pneumonia in
candidate against SARS-CoV-2 in human volunteers. medRxiv 2020: mice infected with SARS-CoV. J Immunol 2008; 181: 6337–48.
published online Nov 9. https://doi.org/10.1101/2020.11.09.20228551
(preprint).
1270 www.thelancet.com/infection Vol 21 September 2021
